Among patients with PTCL in SGN35-012, the ORR was 45% (10/22; 95% CI, 24.4%-67.8%) in patients with CD30 expression ≥10%, 33% (4/12; 95% CI, 9.9%-65.1%) in the CD30 <10% group, and 33% (2/6; 95% CI, 4.3%-77.7%) in patients with PTCL with undetectable CD30 expression. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.